Khalid (2023) “ROLE OF SGLT-2 INHIBITORS (GLIFLOZINS) AND CARDIORENAL OUTCOME IN PATIENTS WITH OR WITHOUT DIABETES”, Journal of Population Therapeutics and Clinical Pharmacology, 30(18), pp. 1001–1009. doi:10.53555/jptcp.v30i18.3220.